Investors shift focus from AI hype to core fundamentals for blue-chip stocks like Thermo Fisher Scientific (NYSE: TMO). Stifel analysts recently lowered the price target from $700 to $600 but upheld a buy rating amid ongoing concerns.
Stock Performance and Market Reaction
The company’s shares trade around $467, reflecting a year-to-date decline of 11% and a 19% drop compared to the prior year. Despite challenges during key analyst calls and conference presentations, where momentum faltered for investors, recent developments signal a potential rebound.
Key Factors Driving the Adjustment
Stifel highlights negative pressures from the CEO vacancy and subdued outlook for the Tools business segment. Biopharma accounts for 60% of Thermo Fisher’s sales, with 2026 forecasts for major segments revised downward individually.
In the second quarter, the firm recorded an impairment charge linked to reduced visibility in its core business, prompting expressions of regret from management.
Positive Guidance Amid Declines
Current valuations appear fair, with the company justifying its overall “GOOD” rating. Executives demonstrate confidence through active share purchases.
Thermo Fisher recently updated its first-quarter 2026 guidance, lifting expected earnings per share from $5.25 to $5.44 and raising product sales projections from $108.7 billion to $110.1 billion. Even with these upward revisions, shares declined.
Broader Analyst Sentiment
BofA Securities similarly reduced its target from $700 to $630 while keeping a buy recommendation. These moves align with recent forecast adjustments and reflect tempered expectations around leadership transitions and seasonal sales patterns.
Stifel anticipates a possible second-half recovery driven by typical seasonal upticks, encouraging investor engagement.
